Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluciclovine (18F) PET in Prostate Cancer With Negative/Equivocal PSMA PET
NCT07569926Phase 4Recruiting
- Sponsor
- Blue Earth Diagnostics
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by Blue Earth Diagnostics. Started Aug 2026; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07569926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569926.